The US Food and Drug Administration (FDA) has approved argenx’s VYVGART Hytrulo to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
Intended for use as a once-a-week 30-to-90-second subcutaneous injection, VYVGART Hytrulo is the first and only neonatal Fc receptor…
[ad_2]
Source link
